Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention
In patients undergoing PCI, moderate-intensity statin plus ezetimibe demonstrated a similar risk of MACCEs but a lower risk of new-onset DM than high-intensity statin. Early combination treatment of moderate-intensity statin and ezetimibe may be a useful and safe lipid-lowering strategy after PCI.
Authors
- Sungmin Lim (ORCID: https://orcid.org/0000-0003-4833-4440)
- Eun Ho Choo (ORCID: https://orcid.org/0000-0003-3166-3176)
- Kiyuk Chang (ORCID: https://orcid.org/0000-0003-3456-8705)
- Donggyu Moon (ORCID: https://orcid.org/0000-0003-4927-3248)
- Ik Jun Choi (ORCID: https://orcid.org/0000-0001-9996-2346)
- Doo Soo Jeon (ORCID: https://orcid.org/0000-0001-6270-6621)
- Ki‐Dong Yoo (ORCID: https://orcid.org/0000-0001-5425-1102)
- Byung‐Hee Hwang (ORCID: https://orcid.org/0000-0001-7770-0791)
- Chan Joon Kim (ORCID: https://orcid.org/0000-0003-2929-8325)
- Dongwoo Kang (ORCID: https://orcid.org/0000-0002-6250-9908)
- Jungkuk Lee (ORCID: https://orcid.org/0000-0003-1874-449X)
- Jong Min Lee (ORCID: https://orcid.org/0000-0002-0165-5856)
Institutions
- The Catholic University of Korea St. Vincent's Hospital (KR)
- Hanmi Pharmaceutical (South Korea) (KR)
- The Catholic University of Korea Incheon St. Mary's Hospital (KR)
- The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1186/s12933-024-02498-3
- Citations
- 9
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 5.15